Table 2.

Gene Methylation Detection, Sensitivity, Specificity Using Detectable vs. Non-detectable cutoff

	Cancer (n=74)		Control (n=25)
Plasma	n	Sensitivity	n	Specificity	PPV	NPV	AUC	AUC 95% CI
CDO1	56	76%	11	56%	84%	44%	0.68	0.55–0.80
TAC1	61	82%	10	60%	86%	54%	0.73	0.61–0.86
HOXA7	55	74%	4	84%	93%	53%	0.79	0.69–0.90
HOXA9	43	58%	5	80%	90%	39%	0.66	0.54–0.77
SOX17	59	80%	9	64%	87%	52%	0.75	0.63–0.86
ZFP42	69	93%	18	28%	79%	58%	0.70	0.58–0.82
All (at least 3 positive)	65	88%	10	60%	87%	63%	0.68	0.56–0.80
	Cancer (n=71)		Control (n=27)
Urine	n	Sensitivity	n	Specificity	PPV	NPV	AUC	AUC 95% CI
CDO1	51	72%	10	63%	84%	46%	0.70	0.58–0.82
TAC1	48	68%	7	74%	87%	47%	0.70	0.58–0.83
HOXA7	36	51%	12	56%	75%	30%	0.54	0.41–0.67
HOXA9	34	48%	5	81%	87%	37%	0.66	0.54–0.77
SOX17	56	79%	9	67%	86%	55%	0.76	0.65–0.88
ZFP42	65	92%	21	22%	76%	50%	0.65	0.52–0.77
All (at least 3 positive)	66	93%	19	30%	78%	62%	0.70	0.58–0.81
	Cancer (n=71)		Control (n=27)
Plasma and Urine	n	Sensitivity	n	Specificity	PPV	NPV	AUC	AUC 95% CI
CDO1	42	58%	4	85%	91%	42%	0.69	0.5–0.82
TAC1	39	53%	2	92%	95%	41%	0.72	0.59–0.85
HOXA7	32	45%	4	85%	89%	37%	0.70	0.58–0.82
HOXA9	20	27%	1	96%	95%	33%	0.77	0.66–0.87
SOX17	47	65%	3	88%	94%	48%	0.78	0.67–0.89
ZFP42	60	85%	17	32%	78%	42%	0.72	0.60–0.84
All (at least 3 positive)	52	73%	2	92%	96%	55%	0.72	0.61–0.84

Abbreviations: Area under the curve: AUC; positive predictive value: PPV; negative predictive value: NPV.